🇺🇸 FDA
Patent

US 6664230

Orally administered peptides to ameliorate atherosclerosis

expired A61KA61K38/00A61P

Quick answer

US patent 6664230 (Orally administered peptides to ameliorate atherosclerosis) held by The Regents of the University of California expires Mon Dec 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Dec 16 2003 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
61
CPC classes
A61K, A61K38/00, A61P, A61P11/00, A61P17/00